首页> 外文期刊>Carcinogenesis >MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer
【24h】

MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer

机译:MicroRNA分析和I期肺癌复发/无复发生存率预测

获取原文
获取原文并翻译 | 示例
           

摘要

About 30% stage I non-small cell lung cancer (NSCLC) patients undergoing resection will recur. Robust prognostic markers are required to better manage therapy options. MicroRNAs (miRNAs) are a class of small non-coding RNAs of 19-25 nt and play important roles in gene regulation in human cancers. The purpose of this study is to identify miRNA expression profiles that would better predict prognosis of stage I NSCLC. MiRNAs extracted from 527 stage I NSCLC patients were profiled on the human miRNA expression profiling v2 panel (Illumina). The expression profiles were analyzed for their association with cancer subtypes, lung cancer brain metastasis and recurrence/relapse free survival (RFS). MiRNA expression patterns between lung adenocarcinoma and squamous cell carcinoma differed significantly with 171 miRNAs, including Let-7 family members and miR-205. Ten miRNAs associated with brain metastasis were identified including miR-145*, which inhibit cell invasion and metastasis. Two miRNA signatures that are highly predictive of RFS were identified. The first contained 34 miRNAs derived from 357 stage I NSCLC patients independent of cancer subtype, whereas the second containing 27 miRNAs was adenocarcinoma specific. Both signatures were validated using formalin-fixed paraffin embedded and/or fresh frozen tissues in independent data set with 170 stage I patients. Our findings have important prognostic or therapeutic implications for the management of stage I lung cancer patients. The identified miRNAs hold great potential as targets for histology-specific treatment or prevention and treatment of recurrent disease.
机译:大约30%接受切除的I期非小细胞肺癌(NSCLC)患者会复发。需要强有力的预后标志物以更好地管理治疗方案。微小RNA(miRNA)是一类19-25 nt的小型非编码RNA,在人类癌症的基因调控中起着重要作用。这项研究的目的是确定miRNA表达谱,可以更好地预测I期NSCLC的预后。在人miRNA表达谱v2面板(Illumina)上分析了从527位I期NSCLC患者中提取的miRNA。分析了表达谱与癌症亚型,肺癌脑转移和复发/无复发生存期(RFS)的关系。肺腺癌和鳞状细胞癌之间的miRNA表达模式与171个miRNA显着不同,其中包括Let-7家族成员和miR-205。鉴定了与脑转移相关的十种miRNA,包括抑制细胞侵袭和转移的miR-145 *。确定了两个可高度预测RFS的miRNA特征。第一个包含来自357位I期NSCLC患者的34个miRNA,独立于癌症亚型,而第二个包含27个miRNA是腺癌特异性的。使用福尔马林固定石蜡包埋的和/或新鲜冷冻的组织在170例I期患者的独立数据集中验证了这两个特征。我们的发现对I期肺癌患者的治疗具有重要的预后或治疗意义。鉴定出的miRNA具有作为组织学特异性治疗或预防和治疗复发性疾病的靶标的巨大潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号